FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336695065> ?p ?o ?g. }

• W2336695065 endingPage "1153" @default.
• W2336695065 startingPage "1146" @default.
• W2336695065 abstract "In the adjuvant setting for malignant melanoma, interferon (IFN)-α-2b and pegylated (PEG) IFN-α-2b were approved in several countries including the USA before these were approved in Japan. To resolve the drug-lag issue, this phase I study was designed to evaluate the safety and tolerability in Japanese patients with stage II or III malignant melanoma who had undergone surgery, by treating with PEG IFN-α-2b. As with a previously reported phase III study, patients were to receive PEG IFN-α-2b 6 μg/kg per week s.c. during an 8-week induction phase, followed by a maintenance phase at a dose of 3 μg/kg per week up to 5 years. Dose-limiting toxicity and pharmacokinetics were assessed during the initial 8 weeks. Of the nine patients enrolled, two patients had dose-limiting toxicities that resolved after discontinuation of treatment. The most frequently reported drug-related adverse events (DRAE) included pyrexia, decreased neutrophil and white blood cell counts, and arthralgia. Grade 3 DRAE included decreased neutrophil count. No deaths, serious adverse events and grade 4 adverse events were reported. Distant metastasis occurred in one patient. No apparent differences in area under the concentration-time curve and maximum observed serum concentration were observed between Japanese and historical non-Japanese pharmacokinetic data, suggesting no marked racial differences. No neutralizing antibody was detected in these patient samples. PEG IFN-α-2b was tolerated in Japanese patients, and eventually approved in Japan in May 2015 for adjuvant therapy in patients with stage III malignant melanoma. Because the number of patients was limited, further investigation would be crucial." @default.
• W2336695065 created "2016-06-24" @default.
• W2336695065 creator A5001893646 @default.
• W2336695065 creator A5012561869 @default.
• W2336695065 creator A5040778303 @default.
• W2336695065 creator A5042799216 @default.
• W2336695065 creator A5050952919 @default.
• W2336695065 creator A5052576209 @default.
• W2336695065 creator A5057450881 @default.
• W2336695065 date "2016-10-01" @default.
• W2336695065 modified "2023-09-23" @default.
• W2336695065 title "Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma" @default.
• W2336695065 cites W1828940258 @default.
• W2336695065 cites W1838790680 @default.
• W2336695065 cites W1854203388 @default.
• W2336695065 cites W1996799221 @default.
• W2336695065 cites W1998698384 @default.
• W2336695065 cites W2031188948 @default.
• W2336695065 cites W2070825440 @default.
• W2336695065 cites W2099289479 @default.
• W2336695065 cites W2108377206 @default.
• W2336695065 cites W2114160093 @default.
• W2336695065 cites W2157424606 @default.
• W2336695065 cites W2161671887 @default.
• W2336695065 cites W2164130643 @default.
• W2336695065 cites W2167162853 @default.
• W2336695065 cites W2167925208 @default.
• W2336695065 cites W2238169772 @default.
• W2336695065 doi "https://doi.org/10.1111/1346-8138.13338" @default.
• W2336695065 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5108434" @default.
• W2336695065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27087489" @default.
• W2336695065 hasPublicationYear "2016" @default.
• W2336695065 type Work @default.
• W2336695065 sameAs 2336695065 @default.
• W2336695065 citedByCount "8" @default.
• W2336695065 countsByYear W23366950652018 @default.
• W2336695065 countsByYear W23366950652019 @default.
• W2336695065 countsByYear W23366950652020 @default.
• W2336695065 countsByYear W23366950652023 @default.
• W2336695065 crossrefType "journal-article" @default.
• W2336695065 hasAuthorship W2336695065A5001893646 @default.
• W2336695065 hasAuthorship W2336695065A5012561869 @default.
• W2336695065 hasAuthorship W2336695065A5040778303 @default.
• W2336695065 hasAuthorship W2336695065A5042799216 @default.
• W2336695065 hasAuthorship W2336695065A5050952919 @default.
• W2336695065 hasAuthorship W2336695065A5052576209 @default.
• W2336695065 hasAuthorship W2336695065A5057450881 @default.
• W2336695065 hasBestOaLocation W23366950651 @default.
• W2336695065 hasConcept C112705442 @default.
• W2336695065 hasConcept C121608353 @default.
• W2336695065 hasConcept C126322002 @default.
• W2336695065 hasConcept C143998085 @default.
• W2336695065 hasConcept C197934379 @default.
• W2336695065 hasConcept C203014093 @default.
• W2336695065 hasConcept C2522874641 @default.
• W2336695065 hasConcept C2776178377 @default.
• W2336695065 hasConcept C2776408679 @default.
• W2336695065 hasConcept C2776461080 @default.
• W2336695065 hasConcept C2777658100 @default.
• W2336695065 hasConcept C2777863537 @default.
• W2336695065 hasConcept C2777982462 @default.
• W2336695065 hasConcept C2778375690 @default.
• W2336695065 hasConcept C2778715236 @default.
• W2336695065 hasConcept C2780040827 @default.
• W2336695065 hasConcept C2909179924 @default.
• W2336695065 hasConcept C29730261 @default.
• W2336695065 hasConcept C31760486 @default.
• W2336695065 hasConcept C502942594 @default.
• W2336695065 hasConcept C71924100 @default.
• W2336695065 hasConcept C90924648 @default.
• W2336695065 hasConceptScore W2336695065C112705442 @default.
• W2336695065 hasConceptScore W2336695065C121608353 @default.
• W2336695065 hasConceptScore W2336695065C126322002 @default.
• W2336695065 hasConceptScore W2336695065C143998085 @default.
• W2336695065 hasConceptScore W2336695065C197934379 @default.
• W2336695065 hasConceptScore W2336695065C203014093 @default.
• W2336695065 hasConceptScore W2336695065C2522874641 @default.
• W2336695065 hasConceptScore W2336695065C2776178377 @default.
• W2336695065 hasConceptScore W2336695065C2776408679 @default.
• W2336695065 hasConceptScore W2336695065C2776461080 @default.
• W2336695065 hasConceptScore W2336695065C2777658100 @default.
• W2336695065 hasConceptScore W2336695065C2777863537 @default.
• W2336695065 hasConceptScore W2336695065C2777982462 @default.
• W2336695065 hasConceptScore W2336695065C2778375690 @default.
• W2336695065 hasConceptScore W2336695065C2778715236 @default.
• W2336695065 hasConceptScore W2336695065C2780040827 @default.
• W2336695065 hasConceptScore W2336695065C2909179924 @default.
• W2336695065 hasConceptScore W2336695065C29730261 @default.
• W2336695065 hasConceptScore W2336695065C31760486 @default.
• W2336695065 hasConceptScore W2336695065C502942594 @default.
• W2336695065 hasConceptScore W2336695065C71924100 @default.
• W2336695065 hasConceptScore W2336695065C90924648 @default.
• W2336695065 hasFunder F4320332932 @default.
• W2336695065 hasIssue "10" @default.
• W2336695065 hasLocation W23366950651 @default.
• W2336695065 hasLocation W23366950652 @default.
• W2336695065 hasLocation W23366950653 @default.
• W2336695065 hasLocation W23366950654 @default.

• next